Amylyx Pharmaceuticals (AMLX) 25th Annual Needham Virtual Healthcare Conference summary

Strategic focus and pipeline overview

• Main focus is on avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), with FDA Breakthrough and Orphan Designation and strong patent protection through 2037.

• Additional programs include AMX0035 for Wolfram syndrome, a calpain-2 targeted antisense oligonucleotide for ALS, and a longer-acting GLP-1 antagonist (318) in collaboration with Gubra.

• Company is well-capitalized with over $300 million, expected to fund operations and potential commercial launch into 2028.

• Team remains under 150 people, maintaining a focused approach on rare diseases.

Avexitide clinical development and study design

• Avexitide targets PBH, a severe, rapid-onset hypoglycemia affecting ~8% of bariatric surgery patients, with a U.S. target market estimated at 160,000.

• Five prior studies, including phase I and II, demonstrated significant reductions in hypoglycemic events, with phase II-B showing a 64% reduction and median patient experiencing zero events.

• The ongoing phase III LUCIDITY study uses a 16-week double-blind period, focusing on Roux-en-Y gastric bypass patients, with a composite primary endpoint of level two and three hypoglycemic events.

• Study is powered to detect a 35% difference versus placebo, with results expected in Q3 2025.

• Safety profile has been mild to moderate, with no serious treatment-related adverse events or discontinuations in prior studies.

Market opportunity and patient impact

• Over 2 million bariatric surgeries in the U.S. in the past decade create a substantial orphan market for PBH.

• PBH is highly debilitating, with 85% of affected patients reporting disability and significant lifestyle restrictions.

• No approved therapies currently exist for PBH, highlighting unmet need and first-mover advantage.

• Avexitide aims to restore normalcy for patients unable to manage PBH through diet alone.

• Planning for a 2027 commercial launch, pending positive phase III results and regulatory review.